Examkin

Question

Difficulty: MediumPediatric Cardiovascular Disorders

A 4-year-old boy of East Asian descent is admitted to the pediatric ward with a 6-day history of persistent fever measuring up to 39.8∘C39.8^\circ\text{C} (103.6∘F103.6^\circ\text{F}). His parents report that he has been highly irritable and refuses to eat. On physical examination, the child is tachycardic but normotensive. He has bilateral nonexudative conjunctival injection, cracked and fissured lips, a prominent 'strawberry tongue,' and tender cervical lymphadenopathy. Erythema and edema of the dorsal hands and feet are noted, along with a polymorphous maculopapular rash over the trunk. A baseline transthoracic echocardiogram obtained upon admission shows structurally normal coronary arteries. He is diagnosed with classic Kawasaki disease.

Arrange the following management and follow-up steps in the correct chronological sequence for this patient, starting with immediate inpatient treatment and concluding with long-term outpatient preventive care.

  1. 1Administer intravenous immunoglobulin (IVIG) and high-dose aspirin
  2. 2Transition to low-dose aspirin therapy once the patient is afebrile for 48 hours
  3. 3Perform a follow-up transthoracic echocardiogram at 2 and 6 weeks
  4. 4Discontinue aspirin therapy completely if coronary arteries remain normal
  5. 5Administer the live-attenuated measles, mumps, and rubella (MMR) vaccine

Answer

The correct chronological sequence for the management of Kawasaki disease is: 1) Administer IVIG and high-dose aspirin, 2) Transition to low-dose aspirin therapy once afebrile, 3) Perform follow-up echocardiography at 2 and 6 weeks, 4) Discontinue aspirin if imaging is normal at 6-8 weeks, and 5) Administer live-attenuated vaccines like the MMR vaccine 11 months later.
The correct sequence mirrors the clinical progression of Kawasaki disease management. Immediate intervention (IVIG and high-dose aspirin) is required to halt inflammation and prevent coronary artery aneurysms. Once the acute phase resolves (afebrile for 48 hours), therapy is stepped down to low-dose aspirin to address reactive thrombocytosis. Because aneurysms peak in the subacute phase, follow-up echocardiography is mandated at 2 and 6 weeks. If the coronaries are normal by 6-8 weeks, aspirin is discontinued. Finally, long-term pediatric care must account for the fact that IVIG neutralizes live vaccines, requiring an 11-month delay for MMR administration.

Step-by-Step Solution

1
Identify the primary diagnosis and its immediate threat.
The patient has Kawasaki disease, which carries a high risk of coronary artery aneurysms if systemic inflammation is not rapidly controlled.
Establishing the diagnosis dictates the need for immediate anti-inflammatory therapy with IVIG and high-dose aspirin.
2
Determine the criteria for transitioning medications from the acute to the subacute phase.
The patient transitions to low-dose aspirin (antiplatelet therapy) only after being afebrile for 48 hours.
High-dose aspirin treats the acute inflammation, while low-dose aspirin prevents thrombosis during the subacute phase when thrombocytosis peaks.
3
Establish the timing for critical diagnostic follow-up.
Echocardiograms must be repeated at 2 and 6 weeks post-illness onset.
Coronary aneurysms typically develop weeks after the initial fever; a normal baseline echocardiogram does not eliminate this risk.
4
Determine the endpoint for pharmacological therapy.
Aspirin is discontinued after the 6-to-8-week echocardiogram confirms normal coronary arteries.
The risk of new aneurysm formation passes after 6-8 weeks, removing the need for ongoing antiplatelet prophylaxis.
5
Apply pediatric immunization guidelines regarding blood products.
Live-attenuated vaccines (MMR, Varicella) are deferred for 11 months.
The passive antibodies provided by IVIG will neutralize live vaccine viruses, rendering the immunization ineffective if given prematurely.

Key Concept

Kawasaki disease is managed in distinct chronological phases: immediate anti-inflammatory therapy (IVIG + high-dose aspirin), subacute antiplatelet therapy (low-dose aspirin) with serial echocardiography surveillance at 2 and 6 weeks, cessation of therapy if coronaries are normal, and an 11-month delay of live-attenuated vaccines due to IVIG interference.
Rate this question

Topics

Pediatric Cardiovascular Disorders

More questions from this topic